Document Detail

Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer.
MedLine Citation:
PMID:  23197249     Owner:  NLM     Status:  Publisher    
Malignant ascites is quite rare in breast cancer and is mainly associated with a lobular histology. To date, no studies have evaluated locoregional therapy for malignant ascites in breast cancer. The anti-epithelial cell adhesion molecule (EpCAM), trifunctional antibody catumaxomab was approved in the European Union for the intraperitoneal (i.p.) treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible. We report the case of a 69-year-old female with pretreated breast cancer who received i.p. catumaxomab for the treatment of malignant ascites and showed a regression of liver metastases. The patient originally underwent a left mastectomy and ipsilateral axillary lymph node dissection for an invasive ductal carcinoma in 1995. Following several lines of treatment, she was enrolled in February 2010 in a phase IIIb study (CASIMAS) investigating the safety of a 3-h i.p. catumaxomab infusion. In addition to a local benefit, as shown by an improvement in malignant ascites and a prolongation of the paracentesis-free interval with i.p. catumaxomab, a computed tomography scan, performed some weeks after catumaxomab administration, showed a regression of liver metastases. In addition to a locoregional effect on EpCAM-positive disease, i.p. catumaxomab may also show systemic effects. The use of i.p. catumaxomab for the treatment of malignant ascites due to breast cancer should be explored further in appropriate clinical studies and its possible systemic effects should also be further investigated.
Fausto Petrelli; Karen Borgonovo; Veronica Lonati; Stefano Elia; Sandro Barni
Related Documents :
11142419 - Body size and prostate cancer: a population-based case-control study in china.
23306849 - Hepatocellular carcinoma and other malignancies in autoimmune hepatitis.
12887469 - Sexual factors and prostate cancer.
23587539 - Conducting randomized controlled trials across countries with disparate levels of socio...
12210489 - Prediagnostic toenail cadmium and zinc and subsequent prostate cancer risk.
15815179 - A qualitative analysis of interviews of men with early stage prostate cancer: the prost...
22024969 - Postmenopausal estradiol-progestagen therapy and risk for uterine cervical cancer.
16334809 - Solitary afp- and pivka-ii-producing hepatoid gastric cancer with giant lymph node meta...
15838829 - Invasive breast cancer following ductal and lobular carcinoma in situ of the breast.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-30
Journal Detail:
Title:  Targeted oncology     Volume:  -     ISSN:  1776-260X     ISO Abbreviation:  Target Oncol     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101270595     Medline TA:  Target Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
UO Oncologia, Azienda Ospedaliera Treviglio, Piazzale Ospedale 1, 24047, Treviglio, Bergamo, Italy,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Translational PK-PD modeling in pain.
Next Document:  Effects of Adding Ezetimibe to Fluvastatin on Kidney Function in Patients with Hypercholesterolemia:...